scispace - formally typeset
J

Joseph A. Church

Researcher at University of Southern California

Publications -  240
Citations -  8097

Joseph A. Church is an academic researcher from University of Southern California. The author has contributed to research in topics: Virus & Antibody. The author has an hindex of 43, co-authored 236 publications receiving 7452 citations. Previous affiliations of Joseph A. Church include Boston Children's Hospital & Children's Hospital Los Angeles.

Papers
More filters
Journal ArticleDOI

Identification of Host Proteins Required for HIV Infection Through a Functional Genomic Screen

Joseph A. Church
- 01 Nov 2008 - 
TL;DR: The extraordinary dependence of HIV on human host proteins for efficient transmission and replication provides many new potential targets for antiretroviral therapy.
Journal ArticleDOI

Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States

Antonia Kwan, +84 more
- 20 Aug 2014 - 
TL;DR: Newborn screening in 11 programs in the United States identified SCID in 1 in 58,000 infants, with high survival, and the usefulness of detection of non-SCID T-cell lymphopenia by the same screening remains to be determined.
Journal ArticleDOI

Safety and antiretroviral activity of chronic subcutaneous administration of t-20 in human immunodeficiency virus 1-infected children

Joseph A. Church
- 01 Aug 2003 - 
TL;DR: The use of combination antiretroviral therapy has been associated with a substantial decline in morbidity and mortality in human immunodeficiency virus (HIV)-infected individuals and pharmacologic agents effective at alternative stages in the replication cycle of the virus are identified.
Journal ArticleDOI

Massive Infection and Loss of Memory CD4+ T Cells in Multiple Tissues During Acute SIV Infection

Joseph A. Church
- 01 Aug 2006 - 
TL;DR: This study demonstrated that in this monkey model, memory CD4+ T cells are depleted in multiple tissues during acute SIV infection, and it is strongly suggested that this loss, at least in adult animals and humans, is irreversible.
Journal ArticleDOI

Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn.

TL;DR: Clinically significant infliximab levels were detected in the offspring and the timing of infusions to minimize antibody transfer to the fetus might be an important strategic consideration when therapeutic antibodies are used in pregnancy.